Get the Stockscreener App
3.45
6.76%
-0.25
After Hours:
3.41
-0.04
-1.16%
Pyxis Oncology Inc stock is traded at $3.45, with a volume of 1.28M.
It is down -6.76% in the last 24 hours and up +89.56% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$3.70
Open:
$3.62
24h Volume:
1.28M
Relative Volume:
1.93
Market Cap:
$213.96M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-1.875
EPS:
-1.84
Net Cash Flow:
$-77.44M
1W Performance:
+39.68%
1M Performance:
+89.56%
6M Performance:
+259.86%
1Y Performance:
+6.81%
1-Day Range:
$3.1501
$3.67
1-Week Range:
$2.512
$3.8851
52-Week Range:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
3.45 | 229.47M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Smart tools for monitoring Pyxis Oncology Inc.’s price action2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Can Pyxis Oncology Inc. stock beat analyst upgradesTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - newser.com
How risky is Pyxis Oncology Inc. stock nowJuly 2025 News Drivers & High Conviction Buy Zone Picks - newser.com
Strategies to average down on Pyxis Oncology Inc.Quarterly Investment Review & AI Forecasted Stock Moves - newser.com
Will Pyxis Oncology Inc. stock deliver better than expected guidance2025 Price Targets & Entry Point Confirmation Alerts - newser.com
Will Pyxis Oncology Inc. stock continue upward momentumWeekly Loss Report & Safe Capital Growth Tips - newser.com
Full technical analysis of Pyxis Oncology Inc. stockJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - newser.com
Why Pyxis Oncology Inc. stock is a value investor pickMarket Volume Report & Capital Efficient Trade Techniques - newser.com
Developing predictive dashboards with Pyxis Oncology Inc. data2025 Analyst Calls & Technical Confirmation Trade Alerts - newser.com
Pyxis Oncology Gains 70%, Insider Trades Reap Benefit - 富途牛牛
Pyxis Oncology (NASDAQ:PYXS) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Will Pyxis Oncology Inc. see short term momentumVolume Spike & Pattern Based Trade Signal System - newser.com
Is Pyxis Oncology Inc. stock undervalued vs historical averages2025 Trading Volume Trends & Community Verified Swing Trade Signals - newser.com
Is Pyxis Oncology Inc. stock a top pick in earnings seasonRate Cut & AI Enhanced Trading Signals - newser.com
Real time pattern detection on Pyxis Oncology Inc. stockMarket Growth Report & Community Consensus Picks - newser.com
Pyxis Oncology, Inc. Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets, Effective October 9, 2025 - MarketScreener
Pyxis Oncology appoints Alex Kane as SVP of investor relations By Investing.com - Investing.com Australia
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Quiver Quantitative
Pyxis Oncology appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - MarketScreener
Volume spikes in Pyxis Oncology Inc. stock – what they mean2025 Support & Resistance & Weekly Chart Analysis and Trade Guides - newser.com
What data driven models say about Pyxis Oncology Inc.’s future2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
How institutional ownership impacts Pyxis Oncology Inc. stockMarket Sentiment Review & Daily Momentum Trading Reports - newser.com
What to do if you’re stuck in Pyxis Oncology Inc.Trade Risk Summary & Free High Return Stock Watch Alerts - newser.com
Sector ETF performance correlation with Pyxis Oncology Inc.2025 Investor Takeaways & Low Volatility Stock Recommendations - newser.com
Detecting support and resistance levels for Pyxis Oncology Inc.July 2025 Highlights & Reliable Entry Point Trade Alerts - newser.com
Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell - Defense World
Pyxis Oncology (NASDAQ:PYXS) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Quantitative breakdown of Pyxis Oncology Inc. recent move2025 Technical Patterns & Stepwise Entry/Exit Trade Alerts - newser.com
Live market analysis of Pyxis Oncology Inc.July 2025 Intraday Action & Growth Oriented Trade Recommendations - newser.com
Can swing trading help recover from Pyxis Oncology Inc. lossesAnalyst Downgrade & Pattern Based Trade Signal System - newser.com
Pyxis Oncology, Inc.'s (NASDAQ:PYXS) top owners are retail investors with 39% stake, while 21% is held by institutions - Yahoo Finance
What analysts say about Pyxis Oncology Inc stockHigh Frequency Trading Trends & Next-Level Stock Intelligence, Now Free - earlytimes.in
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
382,518 Stock Options: Pyxis Oncology Awards Major Inducement Grants to New Cancer Drug Development Team - Stock Titan
Pyxis Oncology, Inc. $PYXS Shares Sold by Goldman Sachs Group Inc. - Defense World
Reviewing Akebia Therapeutics (NASDAQ:AKBA) & Pyxis Oncology (NASDAQ:PYXS) - Defense World
Is Pyxis Oncology Inc a good long term investmentRSI Overbought/Oversold & Free Long-Term Investment Planning - earlytimes.in
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):